Ikarian Capital’s Cardiff Oncology CRDF Stock Holding History

Ikarian Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-450,000	Closed	-$1.95M	–	182
2024 Q4	$1.95M	Buy	+450,000	New	+$1.41M	0.27%	81

Other funds holding CRDF

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Ikarian Capital's CRDF Position: Q1 2025 in Review

Ikarian Capital sold out of Cardiff Oncology (CRDF) in Q1 2025, closing a stake of 450,000 shares — an estimated $1.95M sold.

Ikarian Capital first reported a position in CRDF in Q4 2024 and held it in 1 quarter. The position peaked at $1.95M in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2025.

Ikarian Capital reported no remaining Cardiff Oncology position as of Q1 2025 after selling out during the quarter.
Ikarian Capital sold 450,000 Cardiff Oncology shares in Q1 2025, an estimated $1.95M.
Ikarian Capital first reported a position in Cardiff Oncology in Q4 2024 and held it in 1 quarter.
Ikarian Capital's Cardiff Oncology position peaked at $1.95M in Q4 2024.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.